In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biohaven in-licenses CNS compounds BHV3000, BHV3500 from BMS; later restructures deal

Executive Summary

Biohaven Pharmaceuticals Holding Co. Ltd. licensed exclusive, worldwide development and commercialization rights to two of Bristol-Myers Squibb Co.'s CNS development compounds (rimegepant (BHV3000) and BHV3500) and other BMS intellectual property surrounding calcitonin gene-related peptide (CGRP) receptors.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies